Top Markets
Coin of the day
Hillstream BioPharma, Inc. Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc.

HILS
Pozycja w akcjach #37089
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed... Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.
Cena akcji
$0.181
Ostatnia synchronizacja: 2023-10-20
Kapitalizacja rynkowa
$2.03M
Zmiana (1 dzień)
-9.45%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Hillstream BioPharma, Inc. (HILS)

Kategoria

EPS dla Hillstream BioPharma, Inc. (HILS)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Hillstream BioPharma, Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Hillstream BioPharma, Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów